Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F25%3A00082472" target="_blank" >RIV/00159816:_____/25:00082472 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14310/25:00141796

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S8756328225001784?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S8756328225001784?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.bone.2025.117566" target="_blank" >10.1016/j.bone.2025.117566</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review

Popis výsledku v původním jazyce

Giant cell tumor of bone (GCTB) is an intermediate locally aggressive osteolytic tumor with low metastatic potential and a high recurrence rate. It comprises two main types of cells-neoplastic mononuclear stromal cells and osteoclast-like giant cells-which are responsible for the resorption of bone. In addition to surgery, which is the primary treatment of choice, adjuvant therapy is used to lower the risk of recurrence. However, denosumab, the standard adjuvant treatment currently used, only targets osteoclast-like giant cells and does not affect neoplastic stromal cells. Since some GCTBs are inoperable, or even after surgery, there can be residual tumor cells at the site of the tumor, novel therapies, especially those that target neoplastic stromal cells, are needed. Both cell types in GCTB show altered expression of various specific genes and molecules, and these deregulated molecular profiles could serve as biomarkers and targets for targeted therapy. Herein, we summarize the potential biomarkers for both cell types in GCTB and therapeutic agents targeting these molecules with the hope of finding a therapy with improved outcomes and a lower risk of recurrence.

Název v anglickém jazyce

Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review

Popis výsledku anglicky

Giant cell tumor of bone (GCTB) is an intermediate locally aggressive osteolytic tumor with low metastatic potential and a high recurrence rate. It comprises two main types of cells-neoplastic mononuclear stromal cells and osteoclast-like giant cells-which are responsible for the resorption of bone. In addition to surgery, which is the primary treatment of choice, adjuvant therapy is used to lower the risk of recurrence. However, denosumab, the standard adjuvant treatment currently used, only targets osteoclast-like giant cells and does not affect neoplastic stromal cells. Since some GCTBs are inoperable, or even after surgery, there can be residual tumor cells at the site of the tumor, novel therapies, especially those that target neoplastic stromal cells, are needed. Both cell types in GCTB show altered expression of various specific genes and molecules, and these deregulated molecular profiles could serve as biomarkers and targets for targeted therapy. Herein, we summarize the potential biomarkers for both cell types in GCTB and therapeutic agents targeting these molecules with the hope of finding a therapy with improved outcomes and a lower risk of recurrence.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30211 - Orthopaedics

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone

ISSN

8756-3282

e-ISSN

1873-2763

Svazek periodika

199

Číslo periodika v rámci svazku

Oct 2025

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

117566

Kód UT WoS článku

001517069900001

EID výsledku v databázi Scopus

—